Hepatitis is one of the most common irAE causing severe (CTCAE 3–4) toxicity in anti-PD-1 & anti-CTLA4 therapy with incidence rates reported up to 33% [1, 3, 7]. This evidence concerns the gene CTLA4 and Hepatitis.